|Articles|October 1, 2003

October 2003
Volume 9
Issue 10

The Ripple Effects of a Restrictive Medicaid Formulary

Download PDF: The Ripple Effects of a Restrictive Medicaid Formulary

Articles in this issue

almost 23 years ago

Article

Smoking Status Identification: Two Managed Care Organizations' Experiences With a Pilot Project to Implement Identification Systems in Independent Practice Associations

almost 23 years ago

Article

Impact of Maine's Medicaid Drug Formulary Change on Non-Medicaid Markets: Spillover Effects of a Restrictive Drug Formulary

almost 23 years ago

Article

A Clinical Decision and Economic Analysis Model of Cancer Pain Management

almost 23 years ago

Article

Barriers to Mental Health Referral From Pediatric Primary Care Settings

almost 23 years ago

Article

Better Bone Density Reporting: T-score Report Versus Fracture Risk Report With Outcome Analysis

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

The Ripple Effects of a Restrictive Medicaid Formulary

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Ripple Effects of a Restrictive Medicaid Formulary

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo